Posted On: 06/06/2016 6:40:29 PM
Post# of 72443
My response to A17 downplaying the confirmation of P53 activation.
Quote:
Roche: Activating P53 without toxicity is no big deal. We are a $221B company and our scientists discovered Nutlin in 1996. 20 years later we are still in Phase 1 trying to solve the toxicity issue. Cellceutix's Kevetrin just got lucky, that's all.
(0)
(0)
Scroll down for more posts ▼
